gsk

GSK presents positive data for Mo-Rez in platinum-resistant ovarian cancer

GSK plc (LSE/NYSE: GSK) today announced updated data from the global phase I BEHOLD-1 trial for mocertatug rezetecan (Mo-Rez), an investigational B7-H4-targeted antibody-drug conjugate (ADC). Results ...
gsk

GSK delivers strong Q3 performance and continued momentum

Total Q3 sales £8.9 billion +4% AER; +5% CER Specialty Medicines sales £3.9 billion (+15%); HIV sales £2.1 billion (+10%), Respiratory, Immunology & Inflammation £1.1 billion (+21%); Oncology £0.6 ...
gsk

Jemperli (dostarlimab) approved in US as first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer

GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab) as the first and only immunotherapy for adults with stage II and III ...
gsk

Ris-Rez reduced risk of disease progression or death by 67% versus chemotherapy in patients with relapsed osteosarcoma in China

GSK plc (LSE/NYSE: GSK) licensor Hansoh Pharmaceutical Group Co., Ltd., today announced positive results from its ARTEMIS-011 study, a pivotal phase III trial in China evaluating risvutatug rezetecan ...
gsk

GSK showcases pipeline momentum across lung, gynaecological and gastrointestinal cancers at ESMO 2026

AZUR-1 data to show clinically meaningful sustained complete responses with Jemperli (dostarlimab) in MSI-H/dMMR locally advanced rectal cancer GSK plc (LSE/NYSE: GSK) will present more than 20 ...
gsk

ViiV Healthcare’s long-acting HIV treatment Cabenuva (cabotegravir + rilpivirine) meets primary endpoint of superior viral suppression vs. daily oral therapy in people with ...

CROWN is the first large, phase IIIb international trial to evaluate the investigational use of long-acting Cabenuva versus daily oral therapy in people with a history of antiretroviral treatment and ...